-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rituximab Biosimilar in Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rituximab Biosimilar in Non-Hodgkin Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rituximab Biosimilar in Non-Hodgkin Lymphoma Drug Details: Rituximab biosimilar is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rituximab Biosimilar in Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rituximab Biosimilar in Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rituximab Biosimilar in Chronic Lymphocytic Leukemia (CLL) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sym-024 in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sym-024 in Metastatic Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sym-024 in Metastatic Colorectal Cancer Drug Details: Sym-024 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rituximab Biosimilar in Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rituximab Biosimilar in Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rituximab Biosimilar in Chronic Lymphocytic Leukemia (CLL) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Acazicolcept in Sicca Syndrome (Sjogren)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Acazicolcept in Sicca Syndrome (Sjogren) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Acazicolcept in Sicca Syndrome (Sjogren)Drug Details:Acazicolcept is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dalpiciclib in Nasopharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dalpiciclib in Nasopharyngeal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Dalpiciclib in Nasopharyngeal CancerDrug Details:Dalpiciclib isethionate (Erlikon) is a hypoglycemic agent. It is...
-
Company Profile
Apotex Inc – Company Profile
Apotex Inc (Apotex), a subsidiary of SK Capital Partners LP, develops and manufactures generic pharmaceuticals. The company also offers biosimilars, active pharmaceutical ingredients and consumer products. It carries out the research, development, manufacture, and distribution of non-prescription and private label medicines, fine chemicals, and disposable plastics for medical use. The company serves patients, healthcare providers and payers, governments, and other pharmaceutical manufacturers. The company operates through subsidiaries, joint ventures and licensing agreements across the Americas, Europe, the Middle East, Africa,...
Add to Basket -
Product Insights
Restless Legs Syndrome Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update
The restless legs syndrome clinical trial market research report provides an overview of the restless legs syndrome clinical trials scenario. The report provides top-line data relating to the clinical trials on restless legs syndrome. It also includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type.
-
Product Insights
Chronic Lymphocytic Leukemia (CLL) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Chronic lymphocytic leukemia (CLL) is a type of cancer that starts from white blood cells (called lymphocytes) in the bone marrow. It then invades the blood. Symptoms of CLL include abnormal bruising (if platelets are low), fever, infections that keep coming back (recur), loss of appetite or becoming full too quickly (early satiety), and weight loss. Treatment options include surgery, radiation therapy, chemotherapy, or a combination of methods. The CLL pipeline drugs market research report provides comprehensive information on the...